

DAFTAR PUSTAKA

- Abbas, M., Xu, Z., Tan, L. 2017. Epidemiology of parkinson's disease-east versus west. *Movement Disorders Clinical Practice*, 5(1): 14-28.
- Alvarez-Castelao, B., Schuman, E. 2015. The Regulation of Synaptic Protein Turnover. *Journal of Biological Chemistry*, 290(48): 28623-28630.
- Alves, G., Pedersen, K., Bloem, B., Borm, G., Dalaker, T., Beyer, M., Aarsland, D. 2012. Cerebrospinal fluid amyloid-42 and phenotypic heterogeneity in de novo Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*, 84(5): 537-543.
- Ascherio, A., Schwarzschild, M. 2016. The epidemiology of Parkinson's disease: risk factors and prevention. *The Lancet Neurology*, 15(12): 1257-1272.
- Bähr, M., Frotscher, M. 2015. *Ganglia basalis dalam Duus' topical diagnosis in neurology*. Edisi 4. Penerbit Buku kedokteran EGC: 298-301
- Bakker, E., Bacskai, B., Arbel-Ornath, M., Aldea, R., Bedussi, B., Morris, A., Weller, R., Carare, R. 2016. Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases. *Cellular and Molecular Neurobiology*, 36(2): 181-194.
- Bibl, M., Welge, V., Esselmann, H., Wiltfang, J., 2012. Stability of amyloid- β peptides in plasma and serum. *Electrophoresis*, 33(3): 44-450.
- Burn, D. 2006. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy body. *Journal of Neurology, Neurosurgery & Psychiatry*, 77(5): 585-589.
- Carrillo-Mora, P., Luna, R., Colín-Barenque, L. 2014. Amyloid Beta: Multiple Mechanisms of Toxicity and Only Some Protective Effects?. *Oxidative Medicine and Cellular Longevity*, 2014:1-15.
- Chen, G., Xu, T., Yan, Y., Zhou, Y., Jiang, Y., Melcher, K. dan Xu, H. 2017. Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacologica Sinica*, 38(9): 1205-1226

- Chen, M., Inestrosa, N., Ross, G., Fernandez, H., 1995. Platelets Are the Primary Source of Amyloid β -Peptide in Human Blood. *Biochemical and Biophysical Research Communications*, 213(1): 96-103.
- Chen, Z. 2017. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease. *Science Signaling*, 10(488).
- Cheung, Z., Ip, N. 2012. CDK 5: a multifaceted kinase in neurodegenerative diseases. *Trends in Cell Biology*, 22(3):169-175.
- Choi, M., Auyeung Gandhi, S. 2018. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases. *The FEBS Journal*, 285(19):3631-3644.
- Cutler, RG. 2003. *Critical review of Oxidative stress and aging*. Volume I. World Scientific. Singapura
- Dahlan, S. 2013a. *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*. Edisi 3. Salemba Medika. Jakarta:46-49
- Dahlan, S. 2013b. *Statistik untuk kedokteran dan kesehatan*. Edisi 5. Salemba Medika. Jakarta.
- Deane, R. 2004. RAGE (Yin) versus LRP (Yang) Balance regulates Alzheimer amyloid β -peptide clearance through transport across the blood-brain barrier. *Stroke*: 2628-2631.
- Ding, J., Zhang, J., Wang, X., Zhang, L., Jiang, S., Yuan, Y., Li, J., Zhu, L., Zhang, K. 2016. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease. *Journal of Neural Transmission*, 124(3):353-360.
- Dorsey, E. 2018. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology*, 17(11): 939-953.
- Dorsey, E., Constantinescu, R., Thompson, J. 2006. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology*, 68(5): 384-386.

- Fahn, S., Jankovic, J. 2007. Parkinsonisme: *Clinical feature and differential diagnosis dalam Principles and practice of movement disorders*. Philadelphia: Churchill Livingstone/Elsevier:79-95
- Ferguson, L., Rajput, A., Rajput, A., 2015. Early-onset vs. Late-onset Parkinson's disease: A Clinical-pathological Study. *Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques*, 43(1): 113-119.
- French, I., Muthusamy, K. 2018. A Review of the Pedunculopontine Nucleus in Parkinson's Disease. *Frontiers in Aging Neuroscience*, 10.
- Ganguly, G., Chakrabarti, S., Chatterjee, U., Saso, L. 2017. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimers disease and Parkinson disease. *Drug Design, Development and Therapy*, Vol.11: 797-810.
- Giedraitis, V., Sundelöf, J., Irizarry, M., Garevik, N., 2007. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. *Neuroscience Letters*, 427(3):127-131.
- Goetz, C., Tilley, B., Shaftman, S., Stebbins, G., Fahn, S., Martinez-Martin, P., Poewe, W., Dubois, B., Holloway, R., Jankovic, J. 2008. MDS-UPDRS: Scale presentation and clinimetric testing results. *Movement Disorders*, 23(15): 2129-2170.
- Graham, S., Liu, H. 2017. Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. *Ageing Research Reviews*, 34: 30-38.
- Gronewold, J., Klafki, H., Hermann, D., 2015. Factors Responsible for Plasma β -Amyloid Accumulation in Chronic Kidney Disease. *Molecular Neurobiology*, 53(5): 3136-3145.
- Halliday, G., Holton, J., Revesz, T., Dickson, D. 2011. Neuropathology underlying clinical variability in patients with synucleinopathies. *Acta Neuropathologica*, 122(2):187-204.
- Hanon, O., Vidal, J., Bombois, S., Godefroy, O. 2018. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. *Alzheimer's & Dementia*, 14(7): 858-868.

- Helmich, R., Toni, I., Deuschl, G., Bloem, B. 2013. The Pathophysiology of Essential Tremor and Parkinson's Tremor. *Current Neurology and Neuroscience Reports*, 13(9).
- Herb, J., Rane, S., Isaacs, D., Van Wouwe, N., Roman, O., Landman, B. 2016. Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction. *Journal of Parkinson's Disease*, 6(2): 441-451.
- Hirsch, L., Jette, N., Frolkis, A., Steeves, T., Pringsheim, T., 2016. The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Neuroepidemiology*, 46(4): 292-300.
- Inyushin, M., Zayas-Santiagos, A., Rojas, L., 2019. Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. *Histol Histopathol*, 34(8): 843-856.
- Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., Stern, M., Tanner, C., Weiner, W. 1990. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. *Neurology*, 40(10): 1529-1529.
- Jellinger, K. 2014. Neuropathology of Parkinson's Disease. Inflammation in *Parkinson's Disease*. 25-74.
- Kang, J. 2013. Association of Cerebrospinal Fluid β -Amyloid 1-42, T-tau, P-tau181, and α -Synuclein levels with clinical features of drug-naïve patients with early parkinson disease. *JAMA Neurology*.
- Kelompok Studi Gangguan Gerak Perdossi. 2015. *Buku panduan tatalaksana penyakit parkinson dan gangguan gerak lainnya*. Jakarta:7-18
- Kim, S., Allen, N., Canning, C., Fung, V. 2012. Postural Instability in Patients with Parkinson's Disease. *CNS Drugs*, 27(2): 97-112.
- Kim, W., Kagedal, K., Halliday, G., 2014. Alpha-synuclein biology in Lewy body diseases. *Alzheimer's Research & Therapy*.6(5-8).
- Koller, W., Melamed, E. 2007. *Parkinson's disease and related disorders*. 1st ed. Edinburgh: Elsevier.
- Kummer, M., Heneka, M. 2014. Truncated and modified amyloid-beta species. *Alzheimer's Research & Therapy*, 6(3):28.

- Lee Mosley, R., Benner, E., Kadiu, I., Thomas, M., Boska, M., Hasan, K., Laurie, C. and Gendelman, H., 2006. Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. *Clinical Neuroscience Research*, 6(5):261-281.
- Lee, H., Seo, H., Yang, S. 2018. Diabetes and Alzheimer's Disease: Mechanisms and Nutritional Aspects. *Clinical Nutrition Research*, 7(4): 229.
- Lewis, S. 2005. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven Approach. *Journal of Neurology, Neurosurgery & Psychiatry*, 76(3): 343-348.
- Lichter, D., Benedict, R., Hershey, L. 2018. Importance of balance-gait disorder as a risk factor for cognitive impairment, dementia and related non-motor symptoms in Parkinson's disease. *Journal of Parkinson's Disease*, 8(4): 539-552.
- Lim, E., Aarsland, D., Ffytche, D., Taddei, R., van Wamelen, D., Wan, Y., Tan, E., Ray Chaudhuri, K. 2018. Amyloid- β and Parkinson's disease. *Journal of Neurology*.
- Liu, Y., Xiang, Y., Wang, Y., Wang, Y., 2014. Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance. *Molecular Neurobiology*, 52(1):115-119.
- Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., Tamburin, S. 2016. Pathophysiology of motor dysfunction in Parkinson's disease as the rationale for drug treatment and rehabilitation. *Parkinson's Disease*, 2016: 1-18.
- Marsh, S., Blurton-Jones, M. 2012. Examining the mechanisms that link β -amyloid and α -synuclein pathologies. *Alzheimer's Research & Therapy*, 4(2):11.
- Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. dan Mucke, L. 2001. Amyloid peptides enhance synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. *Proceedings of the National Academy of Sciences*, 98(21): 12245-12250.
- Mirdamadi, J. 2016. Cerebellar role in Parkinson's disease. *Journal of Neurophysiology*, 116(3): 917-919.

- Mollenhauer, B., Caspell-Garcia, C., Coffey, C., Taylor, P., Shaw, L., Trojanowski, J., Singleton, A., Frasier, M., Marek, K., Galasko, D. 2017. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. *Neurology*, 89(19):1959-1969.
- Moon, H., Paek, S. 2015. Mitochondrial Dysfunction in Parkinson's Disease. *Experimental Neurobiology*, 24(2):103.
- Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G. 2016. Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. *Expert Opinion on Emerging Drugs*, 21(4):377-391.
- Pardossi-Piquard, R., Checler, F. 2011. The physiology of the β -amyloid precursor protein intracellular domain AICD. *Journal of Neurochemistry*, 120: 109-124.
- Park, J., Davis, R., Sue, C. (2018). Mitochondrial Dysfunction in Parkinson's Disease: New Mechanistic Insights and Therapeutic Perspectives. *Current Neurology and Neuroscience Reports*, 18(5).
- Poewe, W., Tanner, C., Halliday, G., Brundin, P., Volkmann, J., Schrag, A., Lang, A. 2017. *Parkinson disease. Nature Reviews Disease Primers*, 3: 17013.
- Rajput, A., Voll, A., Rajput, M., Robinson, C. 2009. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. *Neurology*, 73(3): 206-212.
- Reeve, A., Simcox, E., Turnbull, D., 2014. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?. *Ageing Research Reviews*, 14:19-30.
- Reijnders, J., Ehrt, U., Lousberg, R., Aarsland, D., Leentjens, A. 2009. The association between motor subtypes and psychopathology in Parkinson's disease. *Parkinsonism & Related Disorders*, 15(5): 379-382.
- Rekam Medis RS M. Djamil Padang. 2016-2018.
- Rochester, L., Galna, B., Lord, S., Yarnall, A., Morris, R., Duncan, G., Khoo, T., Mollenhauer, B., Burn, D. 2017. Decrease in A β 42 predicts dopa-resistant gait progression in early Parkinson disease. *Neurology*, 88(16): 1501-1511.
- Russo, I., Bubacco, L., Greggio, E. 2014. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. *Journal of Neuroinflammation*, 11(1):52.

- Schiess, M., Zheng, H., Soukup, V., Bonnen, J., Nauta, H. 2000. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. *Parkinsonism & Related Disorders*, 6(2): 69-76.
- Schrag, A., Schott, J. 2006. Epidemiological, clinical, and genetic characteristics of early-onset Parkinsonism. *The Lancet Neurology*, 5(4):355-363.
- Stebbins, G., Goetz, C., Burn, D., Jankovic, J., Khoo, T., Tilley, B. 2013. How to identify tremor dominant and postural instability/gait difficulty groups with the MDS-UPDRS: Comparison with the unified Parkinson's disease rating scale. *Movement Disorders*, 28(5):668-670.
- Stefanis, L. 2011. Synuclein in Parkinson's Disease. Cold Spring Harbor *Perspectives in Medicine*, 2(2).
- Takahashi, M., Iseki, E., Kosaka, K. 2000. Cyclin-dependent kinase 5 (Cdk5) associated with Lewy body in diffuse Lewy body disease. *Brain Research*, 862(1-2):253-256.
- Terrelonge, M., Marder, K., Weintraub, D., Alcalay, R. 2015. CSF β -Amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. *Journal of molecular Neuroscience*, 58(1):88-92.
- Thenganatt, M., Jankovic, J. 2014. Parkinson Disease Subtypes. *JAMA Neurology*, 71(4):499.
- van der Heeden, J., Marinus, J., Martinez-Martin, P., Rodriguez-Blazquez, C., Geraedts, V., van Hilten, J. 2016. Postural instability and gait are associated with severity and prognosis of Parkinson disease. *Neurology*, 86(24): 2243-2250.
- Wakabayashi, K., Tanji, K., Mori, F., Takahashi, H. 2007. The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α -synuclein aggregates. *Neuropathology*, 27(5): 494-506.
- Wang, Q., Liu, Y., Zhou, J. 2015. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. *Translational Neurodegeneration*, 4(1).
- Weil, R., Lashley, T., Bras, J., Schrag, A., Schott, J. 2017. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy body. *F1000Research*, 6: 1604.

- Willis, A., Evanoff, B., Lian, M., Criswell, S. and Racette, B., 2010. Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. *Neuroepidemiology*, 34(3):143-151.
- Wu, T., Hallett, M. 2013. The cerebellum in Parkinson's disease and parkinsonism in cerebellar disorders. *Brain*, 136(9): e249-e249.
- Yarnall, A., Lashley, T., Ling, H., Burn, D. 2015. Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. *Movement Disorders*, 31(5): 668-675.
- Yoon, S., AhnJo, S. 2012. Mechanisms of Amyloid- β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease. *Biomolecules and Therapeutics*, 20(3): 245-255.
- Zigmond, MJ, Robert, Burke. 2002. *Pathophysiology of Parkinson's Disease dalam Neuropsychopharmacology: The Fifth Generation of Progress*. Philadelphia: Lippincott/Williams & Wilkins: 1781-1789
- Zuo, L., Piao, Y., Li, L., Yu, S., Guo, P., Hu, Y., Lian, T., Wang, R. 2017. Phenotype of postural instability/gait difficulty in PD: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. *Scientific Reports*, 7(1).

